配售事项所得款项总额约为1.95亿港元，而配售事项所得款项净额(经扣除配售佣金及配售事项的其他 相关成本及开支后)约为1.9亿港元。按此基准，净发行价约为每股配售股份90.54港元。 本公司拟按如下方式分配配售事项所得款项净额(经扣除发行费用后)：配售事项所得款项净额的约 60%，或约1.14亿港元，用于为我们的核心产品Tinengotinib在中国正在进行单药治疗胆管癌(CCA)的临 床试验以及我们核心产品的其他适应症的研发提供资金;配售事项所得款项净额的约30%，或约5704万 港元，用于其他产品的研发，包括TT-00973、TT-01488及其他分子;及配售事项所得款项净额的约 10%，或约1901万港元，用于营运资金及一般企业用途。 210万股配售股份相当于紧接完成前现有已发行H股数目的约0.70%及本公司现有已发行股份数目的约 0.53%，及相当于经配发及发行配售股份扩大后的已发行H股数目的约0.69%及本公司已发行股份数目的 约0.53%。 药捷安康-B(02617)发布公告，配售协议所载所有条件已获达成，而完成已于2026年1月20日落实。配售 代理已按配售价每股配售股份92.85港元成功向不少 ...

智通财经APP讯，药捷安康-B(02617)发布公告，配售协议所载所有条件已获达成，而完成已于2026年1 月20日落实。配售代理已按配售价每股配售股份92.85港元成功向不少于六名承配人配售合共210万股配 售股份。 配售事项所得款项总额约为1.95亿港元，而配售事项所得款项净额(经扣除配售佣金及配售事项的其他 相关成本及开支后)约为1.9亿港元。按此基准，净发行价约为每股配售股份90.54港元。 本公司拟按如下方式分配配售事项所得款项净额(经扣除发行费用后)：配售事项所得款项净额的约 60%，或约1.14亿港元，用于为我们的核心产品Tinengotinib在中国正在进行单药治疗胆管癌(CCA)的临 床试验以及我们核心产品的其他适应症的研发提供资金;配售事项所得款项净额的约30%，或约5704万 港元，用于其他产品的研发，包括TT-00973、TT-01488及其他分子;及配售事项所得款项净额的约 10%，或约1901万港元，用于营运资金及一般企业用途。 210万股配售股份相当于紧接完成前现有已发行H股数目的约0.70%及本公司现有已发行股份数目的约 0.53%，及相当于经配发及发行配售股份扩大后的已发行H ...

消息面上，药捷安康此前宣布，拟配售2100万股新股份，每股配售价92.85港元，较1月13日H股收市价 113.2港元折让17.98%，所得款项净额1.9亿港元。其中，60%用于为其核心产品Tinengotinib在中国正在 进行单药治疗胆管癌(CCA)的临床试验以及核心产品的其他适应症的研发提供资金；约30%用于其他产 品的研发，包括TT-00973、TT-01488及其他分子；约10%用于营运资金及一般企业用途。 药捷安康-B(02617)再跌超10%，截至发稿，跌9.02%，报84.7港元，成交额1.17亿港元。 ...

Core Viewpoint - The stock of Zymeworks Inc. (02617) has experienced a decline of over 10%, currently trading at 84.7 HKD, with a transaction volume of 117 million HKD [1] Group 1: Stock Performance - Zymeworks Inc. shares fell by 9.02% to 84.7 HKD as of the latest report [1] - The stock has seen a significant drop following the announcement of a new share placement [1] Group 2: Share Placement Announcement - The company plans to place 21 million new shares at a price of 92.85 HKD per share, representing a discount of 17.98% compared to the closing price of 113.2 HKD on January 13 [1] - The net proceeds from the placement are expected to be 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds will be allocated to clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be utilized for working capital and general corporate purposes [1]

Core Viewpoint - The stock of药捷安康-B (02617) has experienced a significant decline, dropping over 5% and more than 11% in the previous day, indicating market concerns regarding its recent equity placement and pricing strategy [1] Group 1: Stock Performance - As of the latest update, the stock is trading at 95.1 HKD with a trading volume of 82.17 million HKD [1] - The stock has seen a decline of over 5% in the current trading session following a previous drop of more than 11% [1] Group 2: Equity Placement - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] - The expected net proceeds from the placement are around 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds raised will be allocated to clinical trials for the core product Tinengotinib, specifically for its use in treating cholangiocarcinoma (CCA) in China [1] - About 30% of the proceeds will be directed towards the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% is intended for working capital and general corporate purposes [1]

Core Viewpoint - The stock of Zymeworks Inc. (02617) has experienced a significant decline, with a drop of over 5% and a previous plunge of more than 11% [1] Group 1: Stock Performance - As of the latest update, the stock is down 5%, trading at 95.1 HKD, with a trading volume of 82.17 million HKD [1] - The stock has seen a substantial decrease from its closing price of 113.2 HKD on January 13, reflecting a discount of approximately 17.98% on the new share placement price [1] Group 2: Share Placement Details - The company announced a placement of 2.1 million shares, which represents about 0.69% of the enlarged H shares and approximately 0.53% of the total issued shares [1] - The expected net proceeds from the placement are around 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds raised will be allocated to clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be utilized for working capital and general corporate purposes [1]

Group 1 - The core viewpoint of the article is that药捷安康-B (02617) experienced a decline of over 3%, specifically a drop of 3.71%, trading at 109 HKD with a transaction volume of 23.576 million HKD [1] - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] Group 2 - The expected net proceeds from the placement are approximately 190 million HKD, with around 60% allocated for funding clinical trials of the core product Tinengotinib for the treatment of cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% is designated for working capital and general corporate purposes [1]

Core Viewpoint - The company,药捷安康-B (02617), experienced a decline of over 3%, trading at 109 HKD with a transaction volume of 23.576 million HKD following the announcement of a share placement [1] Group 1: Share Placement Details - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] Group 2: Fund Utilization - The expected net proceeds from the placement are approximately 190 million HKD, with around 60% allocated for funding clinical trials of the core product Tinengotinib for the treatment of cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - Approximately 10% of the funds will be directed towards working capital and general corporate purposes [1]

Core Viewpoint - The company,药捷安康, announced a share placement agreement to raise funds for clinical trials and product development, with a significant discount on the share price compared to the market rate [1] Group 1: Share Placement Details - The company entered into a placement agreement with a placement agent to sell 2.1 million shares at a price of HKD 92.85 per share [1] - The placement price represents a discount of approximately 17.98% from the closing price reported on the Hong Kong Stock Exchange on the same day [1] Group 2: Use of Proceeds - The net proceeds from the placement are expected to be approximately HKD 190.14 million [1] - About 60% of the funds will be allocated to clinical trials for the company's core product, Tinengotinib, specifically for its use in treating cholangiocarcinoma (CCA) [1] - Approximately 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be allocated for working capital and general corporate purposes [1]

Core Viewpoint - The company announced a placement agreement to issue 2.1 million shares at a price of HKD 92.85 per share, representing a discount of approximately 17.98% from the closing price of HKD 113.20 on January 13, 2026 [1] Group 1: Placement Details - The placement shares represent about 0.69% of the enlarged issued H shares and approximately 0.53% of the total issued shares after completion [1] - The expected total gross proceeds from the placement are approximately HKD 195 million, with net proceeds estimated at around HKD 190 million [1] - The net issue price is approximately HKD 90.54 per share [1] Group 2: Use of Proceeds - Approximately 60% of the net proceeds will be allocated to fund clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be allocated for working capital and general corporate purposes [1]